GRDN vs DBVT vs ALKS vs OMCL

For growth investors, Guardian Pharmacy Services, Inc.

(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Omnicell, Inc. at 978. 1x. On forward P/E, Omnicell, Inc. is actually cheaper at 22. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Guardian Pharmacy Services, Inc.

(GRDN) delivered a total return of +126. 8%, compared to -69. 4% for Omnicell, Inc. (OMCL). Over 10 years, the gap is even starker: GRDN returned +126. 7% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Guardian Pharmacy Services, Inc.

(GRDN) is the lower-risk stock at 1. 04β versus Omnicell, Inc. 's 1. 34β — meaning OMCL is approximately 29% more volatile than GRDN relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 17% for Guardian Pharmacy Services, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.

(GRDN) is pulling ahead at 17. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Omnicell, Inc.

(OMCL) trades at 22. 4x forward P/E versus 29. 6x for Guardian Pharmacy Services, Inc. — 7. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Guardian Pharmacy Services, Inc.

(GRDN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +126. 7% 10Y return). Both have compounded well over 10 years (GRDN: +126. 7%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GRDN is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; OMCL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.